- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Adlyxin® | AVE-0010 | Lyxumia®
lixisenatide is an approved drug (EMA (2013), FDA (2016))
Compound class: Peptide or derivative
Comment: Lixisenatide is a GLP-1 peptide mimetic. The sequence for this drug differs from native GLP-1 as depicted in , and is largely based on the sequence of exendin-4 from the Gila monster (Heloderma suspectum). Lixisenatide is licensed as a once-daily mealtime GLP-1 receptor agonist administered by sub-cuteneous injection.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Approved to control blood sugar levels in patients with type 2 diabetes, alongside diet and exercise and if required co-administered wiith other antidiabetes medicines.
A fixed-ratio formulation containing lixisenatide and insulin glargine is being evaluated in Phase 3 clinical trial for the treatment of type 2 diabetes (see NCT02787551).
|Mechanism Of Action and Pharmacodynamic Effects|
|Acts as a GLP-1 receptor agonist and mimics the action of endogenous GLP-1 peptide in controlling blood sugar levels via improved insulin and glucagon secretion and decreased food intake.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02787551||Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period||Phase 3 Interventional||Sanofi|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)